KDMN News and Press, Kadmon Holdings Inc. From 09/17/19

NEW YORK, NY / ACCESSWIRE / September 17, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved its generic Trientine Hydrochloride Capsules USP, 250 mg. Trientine hydrochloride is used for the treatment of Wilson's dis...

Kadmon Holdings (NYSE: KDMN ) is 2.5% lower after hours following a $200M mixed shelf registration and a secondary filing for holders to offer up to 7.34M shares. More news on: Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Three small-cap drugmakers with very different paths to the big leagues recently drew cheers from a large investment bank. In fact, the bank predicted gains of 181% or better from their previous closing.  Grizzled investors know that biotech stocks rarely live up to eye-popping price tar...

The FDA approves  privately held Boehringer Ingelheim's Ofev (nintedanib) to slow the rate of decline in pulmonary function in adult patients with interstitial lung disease associated with systemic sclerosis , a rare disorder of unknown cause characterized by diffuse scarring and va...

Durect (NASDAQ: DRRX ) initiated with Overweight rating and $5 (201% upside) price target at Cantor Fitzgerald. More news on: DURECT Corporation, Ekso Bionics Holdings, Inc., Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Kadmon Holdings (NYSE: KDMN ) is up 0.8% postmarket after a launch at Overweight by Cantor. More news on: Kadmon Holdings, Inc., Healthcare stocks news, Read more ...

NEW YORK, NY / ACCESSWIRE / September 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will participate in the following investor conferences in September: Citi 14 th Annual Biotech Conference in Boston on ...

NEW YORK, NY / ACCESSWIRE / August 30, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced the appointment of Gregory S. Moss, Esq. as Executive Vice President, General Counsel and Corporate Secretary. Mr. Moss will also serve as the Company’s Chief Compliance Officer. “G...

This article is part of a series that provides an ongoing analysis of the changes made to Dan Loeb's 13F stock portfolio on a quarterly basis. It is based on Third Point's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Dan Loeb's Third Point Portfolio series to get an i...

Company Remains on Track to Report Interim Analysis by End of 2019 NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that KD025-213, an open-label registration trial of KD025 for the treatment of chronic graft-versus-host disease (cGVHD)...